GLP1-RAs and Type 1 Diabetes: A retrospective study of incretin-based therapy use with Open Source AID.
So far in this series we've looked at why incretin therapy might be a useful adjunct to traditional type 1 treatment, and also how the pharmacokinetics might
https://www.diabettech.com/glp1-ra/glp1-ras-and-type-1-diabetes-a-retrospective-study-of-incretin-based-therapy-use-with-open-source-aid/
#GLP1RA #GLP1RA #HybridClosedLoop #Incretinbased #OpenSourceAutomatedInsulinDelivery #OSAID
So far in this series we've looked at why incretin therapy might be a useful adjunct to traditional type 1 treatment, and also how the pharmacokinetics might
https://www.diabettech.com/glp1-ra/glp1-ras-and-type-1-diabetes-a-retrospective-study-of-incretin-based-therapy-use-with-open-source-aid/
#GLP1RA #GLP1RA #HybridClosedLoop #Incretinbased #OpenSourceAutomatedInsulinDelivery #OSAID
GLP1-RAs and Type 1 Diabetes: A retrospective study of incretin-based therapy use with Open Source AID. | Diabettech - Diabetes and Technology
So far in this series we've looked at why incretin therapy might be a useful adjunct to traditional type 1 treatment, and also how the pharmacokinetics might be best used to manage type 1. In this article, we look at the feedback from users of these treatments and some of the positives and negatives that